Elafibranor, a dual agonist of PPAR-α/δ, was reported to resolve MASH and improve hepatic steatosis, ballooning, lobular inflammation, and fibrosis in MASLD patients with a fibrosis score ≥ 4. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.